A Simple and Robust Liquid Chromatography With Tandem Mass Spectrometry Analytical Method for Therapeutic Drug Monitoring of Plasma and Cerebrospinal Fluid Polymyxin B1 and B2.
Peile Wang, Qiwen Zhang, Zifei Qin, Han Xing, Min Xu, Hui Pei, Jing Yang, Xiaojian Zhang
Author Information
Peile Wang: Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University.
Qiwen Zhang: Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University.
Zifei Qin: Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University.
Han Xing: Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University.
Min Xu: Departments of Clinical Laboratory and.
Hui Pei: Emergency ICU, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Jing Yang: Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University.
Xiaojian Zhang: Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University.
BACKGROUND: Polymyxin B is used as the last treatment resort for multidrug-resistant gram-negative bacterial infections. This study aimed to develop and validate a simple and robust liquid chromatography with tandem mass spectrometry analytical method for therapeutic drug monitoring of plasma and cerebrospinal fluid (CSF) polymyxin B1 and B2. METHODS: Plasma and CSF polymyxin B1 and B2 were chromatographically separated on a Thermo Hypersil GOLD aQ C18 column and detected using electrospray ionization mode coupled with multiple reaction monitoring. Blood and CSF samples for pharmacokinetic analysis were collected from 15 polymyxin B-treated patients. RESULTS: The calibration curve showed acceptable linearity over 0.2-10 mcg/mL for polymyxin B1 and 0.05-2.5 mcg/mL for B2 in the plasma and CSF, respectively. After validation, according to the Food and Drug Administration (FDA) method validation guideline, this method was applied for polymyxin B1 and B2 quantification in over 100 samples in a clinical study. CONCLUSIONS: A simple and robust method to measure polymyxin B1 and B2 in human CSF was first exploited and validated with good sensitivity and specificity, and successfully applied in polymyxin B pharmacokinetic analysis and therapeutic monitoring in Chinese patients.
References
Velkov T, Roberts KD, Nation RL, et al. Pharmacology of polymyxins: new insights into an “old” class of antibiotics. Future Microbiol. 2013;8:711–724.
Poirel L, Jayol A, Nordmann P. Polymyxins: antibacterial activity, susceptibility testing, and resistance mechanisms encoded by plasmids or chromosomes. Clin Microbiol Rev. 2017;30:557–596.
Orwa JA, Govaerts C, Busson R, et al. Isolation and structural characterization of polymyxin B components. J Chromatogr A. 2001;912:369–373.
He J, Ledesma KR, Lam WY, et al. Variability of polymyxin B major components in commercial formulations. Internat J Antimicrob Ag. 2010;35:308–310.
Tran TB, Velkov T, Nation RL, et al. Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet? Internat J Antimicrob Ag. 2016;48:592–597.
Miglis C, Rhodes NJ, Avedissian SN, et al. Population pharmacokinetics of polymyxin B in acutely ill adult patients. Antimicrob Agents Ch. 2018;62:e01475–17.
Lakota EA, Landersdorfer CB, Nation RL, et al. Personalizing polymyxin B dosing using an adaptive feedback control algorithm. Antimicrob Agents Ch. 2018;62:e00483–18.
Tsuji BT, Pogue JM, Zavascki AP, et al. International consensus guidelines for the optimal use of the polymyxins. Pharmacotherapy. 2019;39:10–39.
Kang JW, Van Schepdael A, Orwa JA, et al. Analysis of polymyxin B sulfate by capillary zone electrophoresis with cyclodextrin as additive: method development and validation. J Chromatogr A. 2000;879:211–218.
Orwa JA, Van Gerven A, Roets E, et al. Liquid chromatography of polymyxin B sulphate. J Chromatogr A. 2000;870:237–243.
Cao GY, Ali FEA, Chiu F, et al. Development and validation of a reversed-phase high-performance liquid chromatography assay for polymyxin B in human plasma. J Antimicrob Chemoth. 2008;62:1009–1014.
Covelli J, Ruszaj D, Straubinger R, et al. The development and validation of simple liquid chromatography–tandem mass spectrometry method for polymyxin B1 and B2 quantification in different matrices. J Chromatogr B. 2017;1065:112–118.
He J, Gao S, Hu M, et al. A validated ultra-performance liquid chromatography–tandem mass spectrometry method for the quantification of polymyxin B in mouse serum and epithelial lining fluid: application to pharmacokinetic studies. J Antimicrob Chemoth. 2013;68:1104–1110.
Cheah SE, Bulitta JB, Li J, et al. Development and validation of a liquid chromatography–mass spectrometry assay for polymyxin B in bacterial growth media. J Pharm Biomed Anal. 2014;92:177–182.
Meng M, Wang LX, Liu S, et al. Simultaneous quantitation of polymyxin B1, polymyxin B2 and polymyxin B1-1 in human plasma and treated human urine using solid phase extraction and liquid chromatography–tandem mass spectrometry. J Chromatogr B. 2016;1012:23–36.
Hee KH, Leaw YKJ, Ong JL, et al. Development and validation of liquid chromatography tandem mass spectrometry method quantitative determination of polymyxin B1, polymyxin B2, polymyxin B3 and isoleucine–polymyxin B1 in human plasma and its application in clinical studies. J Pharm Biomed Anal. 2017;140:91–97.
Thomas TA, Broun EC, Abildskov KM, et al. High performance liquid chromatography-mass spectrometry (LC-MS) assay for polymyxin B1 and B2 in human plasma. Ther Drug Monit. 2012;34:398–9405.
Food and Drug Administration. Guidance for industry: bioanalytical method validation. Available at: www.fda.gov/downloads/drugs/guidances/ucm070107.pdf. Accessed May 24, 2018.
Campbell JL, Le Blanc JCY. Peptide and protein drug analysis by MS: challenges and opportunities for the discovery environment. Bioanalysis. 2011;3:645–657.
Avedissian SN, Liu J, Rhodes NJ, et al. A review of the clinical pharmacokinetics of polymyxin B. Antibiotics. 2019;8:31.
Manchandani P, Thamlikitkul V, Dubrovskaya Y, et al. Population pharmacokinetics of polymyxin B. Clin Pharmacol Ther. 2018;104:534–538.
Manchandani P, Dubrovskaya Y, Gao S, et al. Comparative pharmacokinetic profiling of different polymyxin B components. Antimicrob Agents Ch. 2016;60:6980–6982.
Sandri AM, Landersdorfer CB, Jacob J, et al. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. Clin Infect Dis. 2013;57:524–531.
